A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes.

ABSTRACT:

Background

Patients presenting with parkinsonian syndromes share many clinical features, which can make diagnosis difficult. This is important as atypical parkinsonian syndromes (APSs) such as progressive supranuclear palsy (PSP), multiple system atrophy (MSA) and corticobasal syndrome (CBS) carry a poor prognosis, compared with patients with Parkinson's disease (PD). In addition, there is overlap between APS and dementia diseases, such as Alzheimer's disease (AD) and frontotemporal dementia (FTD).

Objective

To use a panel of cerebrospinal fluid (CSF) biomarkers to differentiate patients with APS from PD and dementia.

Methods

A prospective cohort of 160 patients and 30 control participants were recruited from a single specialist centre. Patients were clinically diagno

SUBMITTER: Magdalinou NK 

PROVIDER: S-EPMC4564944 | biostudies-literature | 2015 Nov

REPOSITORIES: biostudies-literature